Abstract
The growing number and costs of drugs for rare diseases are straining healthcare budgets. Decisions on funding these treatments need to be made on a sound basis
MeSH terms
-
Cost-Benefit Analysis
-
Drug Costs
-
Health Status
-
Humans
-
Orphan Drug Production* / economics
-
Rare Diseases / drug therapy*
-
State Medicine / economics
-
Treatment Outcome